CN1314397C - 一种莲子心有效部位的提取方法 - Google Patents
一种莲子心有效部位的提取方法 Download PDFInfo
- Publication number
- CN1314397C CN1314397C CNB2004100414357A CN200410041435A CN1314397C CN 1314397 C CN1314397 C CN 1314397C CN B2004100414357 A CNB2004100414357 A CN B2004100414357A CN 200410041435 A CN200410041435 A CN 200410041435A CN 1314397 C CN1314397 C CN 1314397C
- Authority
- CN
- China
- Prior art keywords
- plumula nelumbinis
- extract
- extracting method
- effective site
- site according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000284 extract Substances 0.000 title claims abstract description 52
- 240000002853 Nelumbo nucifera Species 0.000 title abstract description 7
- 235000006508 Nelumbo nucifera Nutrition 0.000 title abstract 6
- 235000006510 Nelumbo pentapetala Nutrition 0.000 title abstract 6
- 238000000034 method Methods 0.000 claims abstract description 47
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 41
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 claims abstract description 24
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 24
- 229930013930 alkaloid Natural products 0.000 claims abstract description 18
- 239000006228 supernatant Substances 0.000 claims abstract description 16
- 238000001035 drying Methods 0.000 claims abstract description 14
- 239000002244 precipitate Substances 0.000 claims abstract description 14
- 235000019270 ammonium chloride Nutrition 0.000 claims abstract description 12
- 239000011780 sodium chloride Substances 0.000 claims abstract description 11
- 239000002253 acid Substances 0.000 claims abstract description 10
- 239000012567 medical material Substances 0.000 claims description 19
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 18
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 16
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 10
- XCUCMLUTCAKSOZ-FIRIVFDPSA-N Liensinine Chemical compound C([C@@H]1C=2C=C(C(=CC=2CCN1C)OC)OC=1C(O)=CC=C(C=1)C[C@H]1N(C)CCC=2C=C(C(=CC=21)OC)OC)C1=CC=C(O)C=C1 XCUCMLUTCAKSOZ-FIRIVFDPSA-N 0.000 claims description 9
- XCUCMLUTCAKSOZ-JSOSNVBQSA-N Liensinine Natural products C([C@@H]1C=2C=C(C(=CC=2CCN1C)OC)OC=1C(O)=CC=C(C=1)C[C@@H]1N(C)CCC=2C=C(C(=CC=21)OC)OC)C1=CC=C(O)C=C1 XCUCMLUTCAKSOZ-JSOSNVBQSA-N 0.000 claims description 9
- MIBATSHDJRIUJK-ROJLCIKYSA-N Neferine Chemical compound C1=CC(OC)=CC=C1C[C@@H]1C2=CC(OC=3C(=CC=C(C[C@@H]4C5=CC(OC)=C(OC)C=C5CCN4C)C=3)O)=C(OC)C=C2CCN1C MIBATSHDJRIUJK-ROJLCIKYSA-N 0.000 claims description 9
- AJPXZTKPPINUKN-UHFFFAOYSA-N Isoliensinin Natural products C1=CC(OC)=CC=C1CC1C2=CC(OC=3C(=CC=C(CC4C5=CC(O)=C(OC)C=C5CCN4C)C=3)O)=C(OC)C=C2CCN1C AJPXZTKPPINUKN-UHFFFAOYSA-N 0.000 claims description 8
- AJPXZTKPPINUKN-FIRIVFDPSA-N Isoliensinine Chemical compound C1=CC(OC)=CC=C1C[C@@H]1C2=CC(OC=3C(=CC=C(C[C@@H]4C5=CC(O)=C(OC)C=C5CCN4C)C=3)O)=C(OC)C=C2CCN1C AJPXZTKPPINUKN-FIRIVFDPSA-N 0.000 claims description 8
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 8
- 229910021529 ammonia Inorganic materials 0.000 claims description 8
- 238000007598 dipping method Methods 0.000 claims description 8
- 235000008733 Citrus aurantifolia Nutrition 0.000 claims description 7
- 235000011941 Tilia x europaea Nutrition 0.000 claims description 7
- 239000003513 alkali Substances 0.000 claims description 7
- 239000006071 cream Substances 0.000 claims description 7
- 238000002481 ethanol extraction Methods 0.000 claims description 7
- 239000000469 ethanolic extract Substances 0.000 claims description 7
- 238000000605 extraction Methods 0.000 claims description 7
- 239000004571 lime Substances 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- 230000001376 precipitating effect Effects 0.000 claims description 7
- 238000012546 transfer Methods 0.000 claims description 7
- 238000010992 reflux Methods 0.000 claims description 6
- 239000013543 active substance Substances 0.000 claims description 4
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 3
- 239000001117 sulphuric acid Substances 0.000 claims description 3
- 235000011149 sulphuric acid Nutrition 0.000 claims description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract description 29
- 239000008103 glucose Substances 0.000 abstract description 28
- 210000004369 blood Anatomy 0.000 abstract description 19
- 239000008280 blood Substances 0.000 abstract description 19
- 239000007788 liquid Substances 0.000 abstract description 15
- 239000003814 drug Substances 0.000 abstract description 14
- 206010022489 Insulin Resistance Diseases 0.000 abstract description 12
- 208000011580 syndromic disease Diseases 0.000 abstract description 8
- 230000007170 pathology Effects 0.000 abstract description 6
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract description 6
- 206010020772 Hypertension Diseases 0.000 abstract description 5
- 238000005516 engineering process Methods 0.000 abstract description 5
- 230000000694 effects Effects 0.000 abstract description 3
- 238000002360 preparation method Methods 0.000 abstract description 3
- 201000001421 hyperglycemia Diseases 0.000 abstract description 2
- 150000007513 acids Chemical class 0.000 abstract 1
- 238000000151 deposition Methods 0.000 abstract 1
- 235000019441 ethanol Nutrition 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 57
- 210000004153 islets of langerhan Anatomy 0.000 description 36
- 229940125396 insulin Drugs 0.000 description 29
- 102000004877 Insulin Human genes 0.000 description 28
- 108090001061 Insulin Proteins 0.000 description 28
- 241000700159 Rattus Species 0.000 description 21
- 102100040247 Tumor necrosis factor Human genes 0.000 description 16
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 15
- 210000002966 serum Anatomy 0.000 description 15
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 13
- 206010012601 diabetes mellitus Diseases 0.000 description 12
- 238000001802 infusion Methods 0.000 description 12
- 239000000243 solution Substances 0.000 description 10
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 230000036772 blood pressure Effects 0.000 description 7
- 150000001720 carbohydrates Chemical class 0.000 description 7
- 235000014633 carbohydrates Nutrition 0.000 description 7
- 230000008961 swelling Effects 0.000 description 7
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 6
- 238000004321 preservation Methods 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 210000003191 femoral vein Anatomy 0.000 description 5
- 230000036285 pathological change Effects 0.000 description 5
- 231100000915 pathological change Toxicity 0.000 description 5
- 238000003127 radioimmunoassay Methods 0.000 description 5
- -1 (-)-Neferine chemical compounds Chemical class 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 238000005325 percolation Methods 0.000 description 4
- 238000011552 rat model Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- IYLGZMTXKJYONK-ACLXAEORSA-N (12s,15r)-15-hydroxy-11,16-dioxo-15,20-dihydrosenecionan-12-yl acetate Chemical compound O1C(=O)[C@](CC)(O)C[C@@H](C)[C@](C)(OC(C)=O)C(=O)OCC2=CCN3[C@H]2[C@H]1CC3 IYLGZMTXKJYONK-ACLXAEORSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 206010020718 hyperplasia Diseases 0.000 description 3
- 235000012054 meals Nutrition 0.000 description 3
- 238000007410 oral glucose tolerance test Methods 0.000 description 3
- 210000004279 orbit Anatomy 0.000 description 3
- IYLGZMTXKJYONK-UHFFFAOYSA-N ruwenine Natural products O1C(=O)C(CC)(O)CC(C)C(C)(OC(C)=O)C(=O)OCC2=CCN3C2C1CC3 IYLGZMTXKJYONK-UHFFFAOYSA-N 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- ZKTMLINFIQCERN-QGZVFWFLSA-O Lotusine Chemical compound C([C@@H]1C=2C=C(C(=CC=2CC[N+]1(C)C)O)OC)C1=CC=C(O)C=C1 ZKTMLINFIQCERN-QGZVFWFLSA-O 0.000 description 2
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical group C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 201000008980 hyperinsulinism Diseases 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000003305 oral gavage Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000002798 spectrophotometry method Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 206010062049 Lymphocytic infiltration Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000209477 Nymphaeaceae Species 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 101000648290 Rattus norvegicus Tumor necrosis factor Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- ONBIUAZBGHXJDM-UHFFFAOYSA-J bismuth;potassium;tetraiodide Chemical compound [K+].[I-].[I-].[I-].[I-].[Bi+3] ONBIUAZBGHXJDM-UHFFFAOYSA-J 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 238000004159 blood analysis Methods 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- JAYCTRXMZZRFSD-UHFFFAOYSA-N chloroform;n-ethylethanamine;propan-2-one Chemical compound CC(C)=O.ClC(Cl)Cl.CCNCC JAYCTRXMZZRFSD-UHFFFAOYSA-N 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 239000004459 forage Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000004796 pathophysiological change Effects 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 229960004586 rosiglitazone Drugs 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000004073 vulcanization Methods 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
提取物大剂量组 | 8 | 127.94±16.42** |
提取物大剂量组 | 8 | 6.78±1.75* | 3.58±1.11** |
Claims (13)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2004100414357A CN1314397C (zh) | 2004-07-14 | 2004-07-14 | 一种莲子心有效部位的提取方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2004100414357A CN1314397C (zh) | 2004-07-14 | 2004-07-14 | 一种莲子心有效部位的提取方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1593598A CN1593598A (zh) | 2005-03-16 |
CN1314397C true CN1314397C (zh) | 2007-05-09 |
Family
ID=34665056
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2004100414357A Expired - Lifetime CN1314397C (zh) | 2004-07-14 | 2004-07-14 | 一种莲子心有效部位的提取方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1314397C (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102228515A (zh) * | 2011-06-23 | 2011-11-02 | 中南大学 | 一种分离和富集莲子心总黄酮和总生物碱的方法 |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1319551C (zh) * | 2005-07-18 | 2007-06-06 | 天津大学 | 从莲子心提取挥发油及脂溶性生物总碱的方法 |
CN103040946B (zh) * | 2013-01-30 | 2013-12-11 | 福建中医药大学 | 莲心总生物碱在制备治疗病毒性心肌炎的药物中的用途 |
CN104473952A (zh) * | 2014-11-11 | 2015-04-01 | 济南星懿医药技术有限公司 | 一种治疗糖尿病的药物组合物 |
CN105410931B (zh) * | 2015-11-02 | 2018-07-27 | 华中农业大学 | 一种莲子心清火咀嚼片及其制备方法 |
CN106924258A (zh) * | 2017-01-11 | 2017-07-07 | 中南民族大学 | 莲心碱、异莲心碱和甲基莲心碱制备glut4活性促进剂的用途 |
CN113304191A (zh) * | 2021-06-23 | 2021-08-27 | 冯遵侠 | 一种复方紫杉醇冻干粉 |
CN113663052B (zh) * | 2021-07-30 | 2024-01-16 | 广东康盾制药有限公司 | 一种治疗脑胶质瘤药物组合物及其制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1145250A (zh) * | 1996-09-20 | 1997-03-19 | 缪兴财 | 治疗糖尿病的药剂 |
CN1151314A (zh) * | 1996-08-18 | 1997-06-11 | 白医明 | 一种治疗胰岛素依赖和非依赖型糖尿病药物的制备方法 |
-
2004
- 2004-07-14 CN CNB2004100414357A patent/CN1314397C/zh not_active Expired - Lifetime
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1151314A (zh) * | 1996-08-18 | 1997-06-11 | 白医明 | 一种治疗胰岛素依赖和非依赖型糖尿病药物的制备方法 |
CN1145250A (zh) * | 1996-09-20 | 1997-03-19 | 缪兴财 | 治疗糖尿病的药剂 |
Non-Patent Citations (5)
Title |
---|
HPLC同时测定莲子心中莲心碱和甲基莲心碱的含量 张先洲,等,西北药学杂志,第9卷第6期 1994 * |
HPLC同时测定莲子心中莲心碱和甲基莲心碱的含量 张先洲,等,西北药学杂志,第9卷第6期 1994;薄层色谱法测定莲子心中甲基莲心碱及莲心碱含量 徐平声,等,中国药房,第13卷第4期 2002;莲子心及Nef对实验性糖尿病及肥胖大鼠模型的影响 潘扬,等,南京中医药大学学报,第19卷第4期 2003;莲子心中酚性生物碱3种主要成分定量分析及其特征图谱研究 陈怡,等,中国医院药学杂志,第24卷第4期 2004 * |
莲子心中酚性生物碱3种主要成分定量分析及其特征图谱研究 陈怡,等,中国医院药学杂志,第24卷第4期 2004 * |
莲子心及Nef对实验性糖尿病及肥胖大鼠模型的影响 潘扬,等,南京中医药大学学报,第19卷第4期 2003 * |
薄层色谱法测定莲子心中甲基莲心碱及莲心碱含量 徐平声,等,中国药房,第13卷第4期 2002 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102228515A (zh) * | 2011-06-23 | 2011-11-02 | 中南大学 | 一种分离和富集莲子心总黄酮和总生物碱的方法 |
Also Published As
Publication number | Publication date |
---|---|
CN1593598A (zh) | 2005-03-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1457808A (zh) | 一种铁皮石斛复方制剂及制备和应用 | |
CN1314397C (zh) | 一种莲子心有效部位的提取方法 | |
CN1304039C (zh) | 一种具有降压、降脂、定眩、定风作用的中药组合物及其制备方法和其用途 | |
CN101032504A (zh) | 甘草苷在制药中的应用 | |
CN1709248A (zh) | 一种兰索拉唑冻干粉针剂及其制备方法 | |
CN1726929A (zh) | 一种治疗糖尿病的药物组合物 | |
CN1405314A (zh) | 隐孔菌发酵产物及其制备方法和应用 | |
CN1876038A (zh) | 一种治疗胃腹疾病的中药组合物及其制备方法 | |
CN1861104A (zh) | 可用于治疗糖尿病和高脂血症的旋复花提取物 | |
CN100350940C (zh) | 治疗糖尿病及并发症的药物及其制备方法 | |
CN1152692C (zh) | 蚕沙提取方法、提取物及其用途 | |
CN100339090C (zh) | 新的石榴叶提取物及其医药用途 | |
CN1548142A (zh) | 一种改善糖耐量和治疗糖尿病及肥胖症的药物及其制备方法 | |
CN1287838C (zh) | 一种治疗糖尿病的药物 | |
CN100337623C (zh) | 月季花总黄酮及其制备方法和用途 | |
CN101032534A (zh) | 救必应总皂苷的制备方法及应用 | |
CN1234403C (zh) | 治疗胃病的药物 | |
CN1726916A (zh) | 一种降血糖口崩片及其制备方法 | |
CN1857381A (zh) | 一种沙苑子制剂的质量控制方法 | |
CN1176939C (zh) | 猪牙皂总皂苷及其制备方法与其在制备药物中的应用 | |
CN1557324A (zh) | 蜕皮甾酮在制备治疗胰岛素抵抗药物中的应用 | |
CN1857368A (zh) | 一种治疗糖尿病的药物组合物 | |
CN1947733A (zh) | 一种肿节风软胶囊制剂及其制备方法 | |
CN100335061C (zh) | 水苏糖在制备治疗糖尿病药物中的应用 | |
CN101053598A (zh) | 一种防治心脑血管疾病及糖尿病的药物组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: KANGYUAN PHARMCEUTICAL CO., LTD. Free format text: FORMER OWNER: JIANGSU ZEUKOV PHARMACEUTICAL S. + T. INC. Effective date: 20121205 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 222001 LIANYUNGANG, JIANGSU PROVINCE TO: 222047 LIANYUNGANG, JIANGSU PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20121205 Address after: 222047 Jiangning economic and Technological Development Zone, Jiangsu, Lianyungang industrial city Patentee after: JIANGSU KANION PHARMACEUTICAL Co.,Ltd. Address before: 222001 Jiangsu Province, Lianyungang city Sinpo District Haichang Road No. 58 Patentee before: Jiangsu Zeukov Pharmaceutical S. & T. Inc. |
|
CX01 | Expiry of patent term | ||
CX01 | Expiry of patent term |
Granted publication date: 20070509 |